menopausal disorders	include	perimenopause
menopausal disorders	include	postmenopause
perimenopause	characterized by	irregular menses
perimenopause	associated with	vasomotor symptoms
vasomotor symptoms	include	hot flashes
vasomotor symptoms	include	night sweats
hot flashes	cause	sleep disturbance
night sweats	cause	sleep disturbance
sleep disturbance	reduces	quality of life
estrogen deficiency	leads to	vaginal atrophy
vaginal atrophy	leads to	dyspareunia
dyspareunia	reduces	sexual activity
bone mineral density	decreases with	age
postmenopausal osteoporosis	increases	fracture risk
osteoporosis	diagnosed by	DEXA
DEXA	measures	bone mineral density
bone mineral density	predicts	fracture risk
weight-bearing exercise	improves	bone mineral density
calcium supplementation	supports	bone mineral density
vitamin D supplementation	supports	calcium absorption
bisphosphonates	reduce	fracture risk
denosumab	reduces	fracture risk
hormone replacement therapy	treats	vasomotor symptoms
estrogen therapy	treats	vasomotor symptoms
estrogen therapy	increases	endometrial cancer risk
estrogen-progestin therapy	increases	breast cancer risk
breast cancer risk	associated with	hormone replacement therapy
HRT	contraindicated in	pregnancy
HRT	contraindicated in	thromboembolism
paroxetine	reduces	hot flash frequency
venlafaxine	reduces	hot flash frequency
clonidine	reduces	hot flash frequency
gabapentin	reduces	vasomotor symptoms
soy isoflavones	provide	relief of vasomotor symptoms
nonhormonal therapy	used for	vasomotor symptoms when HRT contraindicated
vaginal estrogen therapy	relieves	vaginal atrophy
vaginal estrogen therapy	improves	vaginal lubrication
genitourinary syndrome of menopause	treated with	vaginal estrogen
genitourinary syndrome of menopause	causes	vaginal dryness
urinary symptoms	common in	menopause
urinary incontinence	worsened by	menopause
genitourinary syndrome of menopause	related to	vaginal health
lipid profile	worsens	postmenopause
HDL cholesterol	decreases	postmenopause
LDL cholesterol	increases	postmenopause
cardiovascular risk	increases	postmenopause
metabolic syndrome	risk increases	postmenopause
weight gain	occurs	menopause
mood changes	associated with	menopause
depression	more common	perimenopause
anxiety	more common	perimenopause
sleep disturbance	common in	menopausal transition
FSH	rises	during menopause
LH	rises	during menopause
estradiol	declines	during menopause
testosterone	declines	during menopause
FSH	diagnostic marker for	menopause
LH	diagnostic marker for	menopause
mammography	recommended for	postmenopausal women
breast cancer screening	recommended for	postmenopausal women
endometrium	thickens	with unopposed estrogen therapy
endometrial hyperplasia	risk increases	unopposed estrogen therapy
progestin	protects	endometrium during estrogen therapy
endometrium	protected by	progestin during estrogen therapy
unopposed estrogen therapy	increases	endometrial hyperplasia
tibolone	used for	menopausal symptoms
menopausal symptoms	relieved by	tibolone
genitourinary syndrome of menopause	reduces	sexual comfort
sertraline	used for	vasomotor symptoms
fluoxetine	used for	vasomotor symptoms
CBT	improves	sleep disturbance
CBT	improves	quality of life
exercise programs	improve	bone mineral density
smoking	worsens	hot flashes
smoking	increases	osteoporosis risk
alcohol consumption	worsens	vasomotor symptoms
physical activity	reduces	cardiovascular risk postmenopause
phytoestrogens	provide	mild relief of vasomotor symptoms
clinical guidelines	influence	menopausal treatment
gynecologist	prescribes	HRT
primary care physician	initiates	menopause assessment
DEXA	recommended for	postmenopausal women
calcium	required for	bone health
calcium carbonate	used for	calcium supplementation
vitamin D	required for	calcium absorption
endometrial cancer	risk increases	unopposed estrogen therapy
breast cancer	risk increases	estrogen-progestin therapy
HRT	monitored by	gynecologist
hysterectomy	impacts	estrogen therapy choice
skin aging	accelerates	postmenopause
hormone therapy	improves	quality of life
thromboembolism	risk increases	hormone therapy
bone loss	mitigated by	calcium supplementation
osteoclast activity	reduced by	bisphosphonates
osteoblast activity	influenced by	estrogen deficiency
endometrial protection	provided by	progestin
family history	influences	osteoporosis risk
calcium intake	associated with	bone mineral density
years since menopause	correlates with	fracture risk
postmenopause care	includes	bone density testing
